Diagnostic utility of APOE, soluble CD40, CD40L, and Aβ1-40 levels in plasma in Alzheimer's disease

Cytokine

Volumn 44, Issue 2, 2008, Pages 283-287

  Ait ghezala, Ghania ^a   Abdullah, Laila ^a   Volmar, Claude Henry ^a   Paris, Daniel ^a   Luis, Cheryl A ^a   Quadros, Amita ^a   Mouzon, Benoit ^a   Mullan, Myles A ^a   Keegan, Andrew P ^a   Parrish, Julia ^a   Crawford, Fiona C ^a   Mathura, Venkatarajan S ^a   Mullan, Michael J ^a  

^a ROSKAMP INSTITUTE   (United States)

Author keywords

Alzheimer; Amyloid beta; ApoE; CD40; Diagnostic

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CD40 ANTIGEN; CD40 LIGAND; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DNA EXTRACTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROGLIA; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIGENS, CD40; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CD40 LIGAND; FEMALE; HUMANS; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY;

EID: 55749084701     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.08.013     Document Type: Article

References (42)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81 2 (2001) 741-766
2. Tandon A., Rogaeva E., Mullan M., and St George-Hyslop P.H. Molecular genetics of Alzheimer's disease: the role of beta-amyloid and the presenilins. Curr Opin Neurol 13 4 (2000) 377-384
3. von Bernhardi R. Glial cell dysregulation: a new perspective on Alzheimer disease. Neurotox Res 12 4 (2007) 215-232
4. von Bernhardi R., Ramirez G., Toro R., and Eugenin J. Pro-inflammatory conditions promote neuronal damage mediated by amyloid precursor protein and decrease its phagocytosis and degradation by microglial cells in culture. Neurobiol Dis 26 1 (2007) 153-164
5. Rojo L.E., Fernandez J.A., Maccioni A.A., Jimenez J.M., and Maccioni R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39 1 (2008) 1-16
6. Bonotis K., Krikki E., Holeva V., Aggouridaki C., Costa V., and Baloyannis S. Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol 193 1-2 (2008) 183-187
7. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21 3 (2000) 383-421
8. Banchereau J., Bazan F., Blanchard D., Briere F., Galizzi J.P., van Kooten C., et al. The CD40 antigen and its ligand. Annu Rev Immunol 12 (1994) 881-922
9. Daoussis D., Andonopoulos A.P., and Liossis S.N. Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol 11 4 (2004) 635-641
10. Chen K., Huang J., Gong W., Zhang L., Yu P., and Wang J.M. CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system. Cell Mol Immunol 3 3 (2006) 163-169
11. Castigli E., Alt F.W., Davidson L., Bottaro A., Mizoguchi E., Bhan A.K., et al. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci USA 91 25 (1994) 12135-12139
12. Kawabe T., Naka T., Yoshida K., Tanaka T., Fujiwara H., Suematsu S., et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1 3 (1994) 167-178
13. Aukrust P., Muller F., Ueland T., Berget T., Aaser E., Brunsvig A., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 6 (1999) 614-620
14. Rosendorff C., Beeri M.S., and Silverman J.M. Cardiovascular risk factors for Alzheimer's disease. Am J Geriatr Cardiol 16 3 (2007) 143-149
15. Skoog I., and Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 28 6 (2006) 605-611
16. Mocali A., Cedrola S., Della Malva N., Bontempelli M., Mitidieri V.A., Bavazzano A., et al. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp Gerontol 39 10 (2004) 1555-1561
17. Desideri G., Cipollone F., Necozione S., Marini C., Lechiara M.C., Taglieri G., et al. Enhanced soluble CD40 ligand and Alzheimer's disease: evidence of a possible pathogenetic role. Neurobiol Aging (2006)
18. Laporte V., Ait-Ghezala G., Volmar C.H., and Mullan M. CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models. J Neuroinflammation 3 (2006) 3
19. Ait-Ghezala G., Volmar C.H., Frieling J., Paris D., Tweed M., Bakshi P., et al. CD40 promotion of amyloid beta production occurs via the NF-kappaB pathway. Eur J Neurosci 25 6 (2007) 1685-1695
20. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61 9 (2003) 1185-1190
21. Suo Z., Tan J., Placzek A., Crawford F., Fang C., and Mullan M. Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res 807 1-2 (1998) 110-117
22. Shaw L.M., Korecka M., Clark C.M., Lee V.M., and Trojanowski J.Q. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6 4 (2007) 295-303
23. Kinoshita J., and Clark T. Alzforum. Methods Mol Biol 401 (2007) 365-381
24. Saunders A.M., Hulette O., Welsh-Bohmer K.A., Schmechel D.E., Crain B., Burke J.R., et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet 348 9020 (1996) 90-93
25. Tsuang D., Larson E.B., Bowen J., McCormick W., Teri L., Nochlin D., et al. The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series. Arch Neurol 56 12 (1999) 1489-1495
26. Welsh-Bohmer K.A., Gearing M., Saunders A.M., Roses A.D., and Mirra S. Apolipoprotein E genotypes in a neuropathological series from the consortium to establish a registry for Alzheimer's disease. Ann Neurol 42 3 (1997) 319-325
27. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 7 (1984) 939-944
28. Bereczki D., Nagy E., Pal A., Magyar M.T., and Balla J. Should soluble CD40 ligand be measured from serum or plasma samples?. Arterioscler Thromb Vasc Biol 23 6 (2003) 1129-1130 (author reply 1130-1121)
29. Tammen H., Schulte I., Hess R., Menzel C., Kellmann M., Mohring T., et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5 13 (2005) 3414-3422
30. Wenham P.R., Sedky A., and Spooner R.J. Apolipoprotein E phenotyping: a word of caution. Ann Clin Biochem 28 Pt. 6 (1991) 599-605
31. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., and Breteler M.M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5 8 (2006) 655-660
32. Graff-Radford N.R., Crook J.E., Lucas J., Boeve B.F., Knopman D.S., Ivnik R.J., et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64 3 (2007) 354-362
33. Van Nostrand W.E., Schmaier A.H., Farrow J.S., and Cunningham D.D. Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. Science 248 4956 (1990) 745-748
34. Olsson A., Vanmechelen E., Vanderstichele H., Davidsson P., and Blennow K. Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets. Dement Geriatr Cogn Disord 16 2 (2003) 93-97
35. Ciabattoni G., Porreca E., Di Febbo C., Di Iorio A., Paganelli R., Bucciarelli T., et al. Determinants of platelet activation in Alzheimer's disease. Neurobiol Aging 28 3 (2007) 336-342
36. Casoli T., Di Stefano G., Giorgetti B., Grossi Y., Balietti M., Fattoretti P., et al. Release of beta-amyloid from high-density platelets: implications for Alzheimer's disease pathology. Ann NY Acad Sci 1096 (2007) 170-178
37. Andre P., Nannizzi-Alaimo L., Prasad S.K., and Phillips D.R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106 8 (2002) 896-899
38. Henn V., Steinbach S., Buchner K., Presek P., and Kroczek R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98 4 (2001) 1047-1054
39. Deane R., Wu Z., Sagare A., Davis J., Du Yan S., Hamm K., et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43 3 (2004) 333-344
40. Deane R., and Zlokovic B.V. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4 2 (2007) 191-197
41. Schonbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 12 (2001) 1092-1103
42. Kukull W.A., Schellenberg G.D., Bowen J.D., McCormick W.C., Yu C.E., Teri L., et al. Apolipoprotein E in Alzheimer's disease risk and case detection: a case-control study. J Clin Epidemiol 49 10 (1996) 1143-1148